Zobrazeno 1 - 10 of 44 pro vyhledávání: '"Robin K. Dore"'
1
Akademický článek
The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States
Autor: Robin K. Dore, Jenya N. Antonova, Chakkarin Burudpakdee, Lawrence Chang, Magdaliz Gorritz, Mark C. Genovese
Publikováno v: ACR Open Rheumatology, Vol 4, Iss 6, Pp 473-482 (2022)
Objective Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and prevalence)
Externí odkaz: https://doaj.org/article/c0dfab1d34814e2183ef6baf5642161b
Zobrazit plný text záznamu
2
Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial
Autor: Yamei Wang, Sanford Baim, Nelson B. Watts, Robin K. Dore, Tamara D. Rozental, Gary Hattersley, Meryl S. LeBoff, Bruce H. Mitlak
Publikováno v: Osteoporosis International
Summary Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0e8c00a526c2c8e5a2f908e56bfae19
https://doi.org/10.1007/s00198-020-05555-1
Zobrazit plný text záznamu
4
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
Autor: Ming Yi Hu, Nancy E Lane, Carol Zapalowski, Andrea Singer, Gary Hattersley, Benjamin Z. Leder, Robin K. Dore
Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol 34, iss 12
Journal of Bone and Mineral Research
In the randomized, placebo-controlled, double-blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of verteb
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28259658f64bd29faa7c0f1c7c44b0e
https://doi.org/10.1002/jbmr.3848
Zobrazit plný text záznamu
5
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
Autor: Robin K. Dore, Stanley N. Cohen, Piet Geusens, Nancy E Lane, Shuang Huang, Willem F. Lems, Jonathan D. Adachi, Robert Kees Stad, Michele McDermott, Li Chen, Kenneth G. Saag
Publikováno v: Saag, K G, McDermott, M T, Adachi, J, Lems, W, Lane, N E, Geusens, P, Stad, R K, Chen, L, Huang, S, Dore, R & Cohen, S 2021, ' The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids ', Arthritis and Rheumatology . https://doi.org/10.1002/art.41981
Arthritis & Rheumatology, 74(4), 604-611. Wiley
Arthritis and Rheumatology. John Wiley and Sons Ltd
Arthritis & rheumatology (Hoboken, N.J.), vol 74, iss 4
ObjectiveTo evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months.MethodsWe conducted a randomized, double-blind, placeb
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89a91e3a4d04b7bab44da79edb392c01
https://research.vumc.nl/en/publications/0436fa7a-8e12-40d2-bf22-6f46e219d9b8
Zobrazit plný text záznamu
6
THU0555 HEALTHCARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS SWITCHING FROM THEIR FIRST CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG TO ANOTHER DISEASE-MODIFYING ANTIRHEUMATIC DRUG REGIMEN
Autor: Robin K. Dore, Jenya Antonova, Magdaliz Gorritz, X. Wang, Mark C. Genovese, L. Chang
Publikováno v: Annals of the Rheumatic Diseases. 79:518-519
Background:EULAR and ACR guidelines recommend a treat-to-target approach for rheumatoid arthritis (RA). For patients failing their first conventional synthetic disease-modifying antirheumatic drug (csDMARD), EULAR recommends switching to or adding an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23d9ce54d923348f2f18e53553e5e85e
https://doi.org/10.1136/annrheumdis-2020-eular.2017
Zobrazit plný text záznamu
7
SAT0066 BURDEN OF MALIGNANCY, VENOUS THROMBOEMBOLISM, ANEMIA, AND INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO SWITCHED FROM A FIRST CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG TO ANOTHER DISEASE-MODIFYING ANTIRHEUMATIC DRUG REGIMEN
Autor: H. Huang, Jenya Antonova, H. Kim, Mark C. Genovese, L. Chang, Robin K. Dore
Publikováno v: Annals of the Rheumatic Diseases. 79:966-967
Background:EULAR and ACR guidelines recommend a variety of treatment options for rheumatoid arthritis (RA) patients who failed a first conventional synthetic disease-modifying antirheumatic drug (csDMARD). The recent launches of Janus kinase inhibito
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec5ea48aed83a8effb5b5c490cc98ebb
https://doi.org/10.1136/annrheumdis-2020-eular.2141
Zobrazit plný text záznamu
8
AB0362 HIGH UNMET NEED AMONG RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARD: REAL-WORLD ANALYSIS OF 2012–2016 US MEDICARE DATA
Autor: Haifeng Guo, Jenya Antonova, Mark C. Genovese, Burak Ozbay, Robin K. Dore, LI Suying
Publikováno v: Abstracts Accepted for Publication.
Background Within treat-to-target approach, ACR recommends biologic DMARD (bDMARD), with or without methotrexate, in rheumatoid arthritis (RA) patients whose disease is active despite methotrexate treatment1. ACR further defines bDMARD failure as the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03851d41557d82d07252a40df6b854b2
https://doi.org/10.1136/annrheumdis-2019-eular.801
Zobrazit plný text záznamu
9
FRI0077 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS
Autor: Magdaliz Gorritz, Jenya Antonova, Mark C. Genovese, Huang Huan, Robin K. Dore
Publikováno v: Poster Presentations.
Background ACR guidelines recommend starting rheumatoid arthritis (RA) treatment with conventional-synthetic (cs)DMARD monotherapy1. If disease activity remains moderate or high, the guidelines recommend adding or switching to another csDMARD, biolog
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::019ac28f689e880e548883e9dad6b456
https://doi.org/10.1136/annrheumdis-2019-eular.1848
Zobrazit plný text záznamu
10
SAT0133 TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)
Autor: Jenya Antonova, X. Wang, Robin K. Dore, Burak Ozbay, Chakkarin Burudpakdee, Mark C. Genovese
Publikováno v: SATURDAY, 15 JUNE 2019.
Background EULAR and ACR recommend bDMARDs, as monotherapy or in combination with methotrexate, in patients whose rheumatoid arthritis (RA) remains active despite methotrexate use.1 Treatment options for bDMARD inadequate response (IR) patients vary.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::799402664b3f2b65ba8ca5189c2c71f3
https://doi.org/10.1136/annrheumdis-2019-eular.2920
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje